Treament of hypertension with a polypill is more effacious than single-drug treatment, according to a randomized, controlled, open-label trial.
The authors stated that pill or tablet burden is a strong predictor of poor patient adherence to antihypertensive therapy, but acknowledged that many recent studies in hypertension and current treatment guidelines emphasize the importance of adequate blood pressure control, which typically requires >1, and often ≥3, agents. They stated that a polypill offers efficacy, cost, and adherence benefits and a reduction in the possibility of drug toxicity.
This study included 108 patients with uncontrolled and treatment-näive hypertension. Mean age was 50+/-1 years; 55% of patients were male; mean systolic blood pressure (SBP) was 160+/-1 mmHg and mean diastolic blood pressure (DBP) was 96+/-1 mmHg. The patients were randomly assigned to receive 1 of 5 once-daily therapies: amlodipine 5 mg (n=22), atenolol 50 mg (n=20), bendroflumethiazide 2.5 mg (n=22), captopril 100 mg (n=22), or a capsule containing one-quarter dose of each of the aforementioned drugs (n=22).
In a related editorial, John L. Reid, DM (doctor of medicine), stated: "This is a relatively short-term study lasting a few weeks but otherwise provides intriguing prospects for enhanced efficacy of multiple-drug combinations in low doses compared with standard therapy."
Approximately 53 million Americans (1 in 3) have been diagnosed with hypertension. Approximately 69% of people who have a first myocardial infarction, 77% who have a first stroke, and 74% who have heart failure also have blood pressures >140/90 mmHg.
SOURCES
Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: More efficacious than individual agents-a preliminary report. Hypertension. 2007;49:272–275.
Reid JL. Fall and rise of polypharmacy? [editorial] Hypertension. 2007;49:266–267.
Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [errata in: Circulation. 2006;113:e696; and Circulation. 2006;114:e630.]Circulation. 2006;113:e85–151.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More